Published in J Biol Chem on March 15, 1987
Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes. Protein Sci (1998) 2.52
Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nat Immunol (2009) 1.98
Structures of C3b in complex with factors B and D give insight into complement convertase formation. Science (2010) 1.59
Small-molecule factor D inhibitors targeting the alternative complement pathway. Nat Chem Biol (2016) 1.41
Structural basis of profactor D activation: from a highly flexible zymogen to a novel self-inhibited serine protease, complement factor D. EMBO J (1999) 1.07
New structural motifs on the chymotrypsin fold and their potential roles in complement factor B. EMBO J (2000) 0.99
Production and functional activity of a recombinant von Willebrand factor-A domain from human complement factor B. Biochem J (1999) 0.85
Purification and partial characterization of rat factor D. Biochem J (1991) 0.82
A structurally dynamic N-terminal helix is a key functional determinant in staphylococcal complement inhibitor (SCIN) proteins. J Biol Chem (2012) 0.81
A novel human complement-related protein, C1r-like protease (C1r-LP), specifically cleaves pro-C1s. Biochem J (2005) 0.79
Effect of N-methylation on the modulation by synthetic peptides of the activity of the complement-factor-B-derived serine proteinase CVFBb. Biochem J (1990) 0.75
Mutants of complement component C3 cleaved by the C4-specific C1-s protease. Proc Natl Acad Sci U S A (1992) 0.75
A comparison of inclusive and restrictive strategies in modern missing data procedures. Psychol Methods (2001) 14.35
Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell (1995) 12.39
F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex. Cell (1997) 11.62
SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell (1996) 11.22
WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res (1994) 9.00
p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell (1994) 7.05
The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev (1999) 6.56
Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science (1992) 6.40
Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science (1999) 6.38
Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science (2001) 6.29
p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. Science (1995) 6.01
The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med (2001) 4.94
p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev (1995) 4.87
Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome. Nature (1997) 4.82
Reconstitution of G1 cyclin ubiquitination with complexes containing SCFGrr1 and Rbx1. Science (1999) 4.65
Insights into SCF ubiquitin ligases from the structure of the Skp1-Skp2 complex. Nature (2000) 4.52
A family of mammalian F-box proteins. Curr Biol (1999) 3.68
How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell (1999) 3.34
Specificity of C-reactive protein for choline phosphate residues of pneumococcal C-polysaccharide. Proc Soc Exp Biol Med (1971) 3.32
Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev (1996) 3.26
SGT1 encodes an essential component of the yeast kinetochore assembly pathway and a novel subunit of the SCF ubiquitin ligase complex. Mol Cell (1999) 3.19
Deletion of p16 and p15 genes in brain tumors. Cancer Res (1994) 3.03
Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme. Proc Natl Acad Sci U S A (1994) 3.03
CAK, the p34cdc2 activating kinase, contains a protein identical or closely related to p40MO15. EMBO J (1993) 2.96
Cell cycle-regulated phosphorylation of p220(NPAT) by cyclin E/Cdk2 in Cajal bodies promotes histone gene transcription. Genes Dev (2000) 2.90
Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Biol Cell (1997) 2.67
Mapping the extended substrate binding site of cathepsin G and human leukocyte elastase. Studies with peptide substrates related to the alpha 1-protease inhibitor reactive site. J Biol Chem (1979) 2.66
p21(CIP1) and p57(KIP2) control muscle differentiation at the myogenin step. Genes Dev (1999) 2.58
Cooperation between the Cdk inhibitors p27(KIP1) and p57(KIP2) in the control of tissue growth and development. Genes Dev (1998) 2.39
Purification of three cytotoxic lymphocyte granule serine proteases that induce apoptosis through distinct substrate and target cell interactions. J Exp Med (1992) 2.25
Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57KIP2, on chromosome 11p15. Proc Natl Acad Sci U S A (1996) 2.17
Rabbit C1q: purification, functional and structural studies. J Immunol Methods (1972) 2.15
Sensitive substrates for human leukocyte and porcine pancreatic elastase: a study of the merits of various chromophoric and fluorogenic leaving groups in assays for serine proteases. Anal Biochem (1979) 2.15
Cdk inhibitors: on the threshold of checkpoints and development. Curr Opin Cell Biol (1994) 2.12
Phosphorylation independent activation of human cyclin-dependent kinase 2 by cyclin A in vitro. Mol Biol Cell (1993) 2.11
CDK2 encodes a 33-kDa cyclin A-associated protein kinase and is expressed before CDC2 in the cell cycle. Proc Natl Acad Sci U S A (1992) 2.05
Genetic disruption of the murine complement C3 promoter region generates deficient mice with extrahepatic expression of C3 mRNA. Immunopharmacology (1999) 1.94
Anticancer drug targets: cell cycle and checkpoint control. J Clin Invest (1999) 1.93
Three dimensional structure of human C-reactive protein. Nat Struct Biol (1996) 1.87
Adipsin and complement factor D activity: an immune-related defect in obesity. Science (1989) 1.87
Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens. Infect Immun (1989) 1.86
Specificity of porcine pancreatic elastase, human leukocyte elastase and cathepsin G. Inhibition with peptide chloromethyl ketones. Biochim Biophys Acta (1977) 1.84
Purification of heparin-binding growth factors. Anal Biochem (1986) 1.78
Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in mice. J Immunol (1982) 1.77
Human and murine cytotoxic T lymphocyte serine proteases: subsite mapping with peptide thioester substrates and inhibition of enzyme activity and cytolysis by isocoumarins. Biochemistry (1991) 1.77
Interaction of C-reactive protein with artificial phosphatidylcholine bilayers. Nature (1979) 1.75
Complement activation by C-reactive protein complexes. Ann N Y Acad Sci (1982) 1.75
Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex. Biochemistry (1992) 1.74
Human leukocyte and porcine pancreatic elastase: X-ray crystal structures, mechanism, substrate specificity, and mechanism-based inhibitors. Biochemistry (1989) 1.68
Interaction of C-reactive protein complexes with the complement system. II. Consumption of guinea pig complement by CRP complexes: requirement for human C1q. J Immunol (1974) 1.68
Retinoblastoma protein contains a C-terminal motif that targets it for phosphorylation by cyclin-cdk complexes. Mol Cell Biol (1999) 1.68
Deletion of the Cul1 gene in mice causes arrest in early embryogenesis and accumulation of cyclin E. Curr Biol (1999) 1.63
Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in transgenic mice. J Immunol (1995) 1.61
Role of complement in C-reactive-protein-mediated protection of mice from Streptococcus pneumoniae. Infect Immun (1996) 1.60
Reaction of serine proteases with substituted isocoumarins: discovery of 3,4-dichloroisocoumarin, a new general mechanism based serine protease inhibitor. Biochemistry (1985) 1.60
Complement activation in factor D-deficient mice. Proc Natl Acad Sci U S A (2001) 1.59
Interaction between cyclin-dependent kinases and human papillomavirus replication-initiation protein E1 is required for efficient viral replication. Proc Natl Acad Sci U S A (1999) 1.59
S-Phase entry upon ectopic expression of G1 cyclin-dependent kinases in the absence of retinoblastoma protein phosphorylation. Curr Biol (1997) 1.48
An x-ray crystallographic study of the binding of peptide chloromethyl ketone inhibitors to subtilisin BPN'. Biochemistry (1972) 1.44
A question of balance: the role of cyclin-kinase inhibitors in development and tumorigenesis. Trends Cell Biol (1996) 1.43
Immune complexes in congenital and natal cytomegalovirus infections of man. J Clin Invest (1977) 1.42
Blood clearance of Streptococcus pneumoniae by C-reactive protein. J Immunol (1987) 1.42
Selective isotopic enrichment of synthetic RNA: application to the HIV-1 TAR element. Biochemistry (1993) 1.40
The role of protein stability in the cell cycle and cancer. Biochim Biophys Acta (1998) 1.34
Human factor D of the alternative complement pathway: purification and characterization. J Immunol (1977) 1.33
Functional interaction of human immunodeficiency virus type 1 Vpu and Gag with a novel member of the tetratricopeptide repeat protein family. J Virol (1998) 1.32
Pseudomonas aeruginosa elastase. Development of a new substrate, inhibitors, and an affinity ligand. J Biol Chem (1980) 1.29
Individuals with IgA deficiency and common variable immunodeficiency share polymorphisms of major histocompatibility complex class III genes. Proc Natl Acad Sci U S A (1989) 1.29
G1 cyclin-dependent kinases are sufficient to initiate DNA synthesis in quiescent human fibroblasts. Curr Biol (1998) 1.28
Structural evidence that complement factor B constitutes a novel class of serine protease. J Biol Chem (1980) 1.26
Susceptibility locus for IgA deficiency and common variable immunodeficiency in the HLA-DR3, -B8, -A1 haplotypes. Mol Med (1998) 1.22
Ascending projections of the cerebellar fastigial nucleus to the hippocampus, amygdala, and other temporal lobe sites: evoked potential and histological studies in monkeys and cats. Exp Neurol (1974) 1.22
Interaction of C-reactive protein with artificial phosphatidylcholine bilayers and complement. J Immunol (1981) 1.22
Expression of Met-(-1) angiogenin in Escherichia coli: conversion to the authentic less than Glu-1 protein. Anal Biochem (1988) 1.20
Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement--III. Inhibition of C4 and C2 binding site(s) on C1s by polyanions. Immunochemistry (1976) 1.20
Immune complexes and other laboratory features of pleural effusions: a comparison of rheumatoid arthritis, systemic lupus erythematosus, and other diseases. Ann Intern Med (1980) 1.19
Active-site specific inhibitors of elastase. Biochemistry (1973) 1.19
Modelling of the serine-proteinase fold by X-ray and neutron scattering and sedimentation analyses: occurrence of the fold in factor D of the complement system. Biochem J (1993) 1.19
The rational use of drains after cholecystectomy. Surg Gynecol Obstet (1978) 1.19
Inhibition of thermolysin and carboxypeptidase A by phosphoramidates. Biochemistry (1979) 1.18
The human cytotoxic T cell granule serine protease granzyme H has chymotrypsin-like (chymase) activity and is taken up into cytoplasmic vesicles reminiscent of granzyme B-containing endosomes. J Biol Chem (1999) 1.18
C-reactive protein: structural biology, gene expression, and host defense function. Immunol Res (1997) 1.18
The oncoprotein kinase chaperone CDC37 functions as an oncogene in mice and collaborates with both c-myc and cyclin D1 in transformation of multiple tissues. Mol Cell Biol (2000) 1.18
The 1.8 A crystal structure of human cathepsin G in complex with Suc-Val-Pro-PheP-(OPh)2: a Janus-faced proteinase with two opposite specificities. EMBO J (1996) 1.17
Granzymes (lymphocyte serine proteases): characterization with natural and synthetic substrates and inhibitors. Biochim Biophys Acta (2000) 1.17
Structure of human factor D. A complement system protein at 2.0 A resolution. J Mol Biol (1994) 1.17
Structures of native and complexed complement factor D: implications of the atypical His57 conformation and self-inhibitory loop in the regulation of specific serine protease activity. J Mol Biol (1998) 1.16
Mammalian tissue trypsin-like enzymes. Comparative reactivities of human skin tryptase, human lung tryptase, and bovine trypsin with peptide 4-nitroanilide and thioester substrates. J Biol Chem (1983) 1.16
The proteoglycan decorin binds C1q and inhibits the activity of the C1 complex. J Immunol (1992) 1.16
X-ray structures of human neutrophil collagenase complexed with peptide hydroxamate and peptide thiol inhibitors. Implications for substrate binding and rational drug design. Eur J Biochem (1995) 1.15